Transaction in own shares

December 21, 2007 Group News
Tags

Cryo-Save Group N.V. (the “Company”) yesterday acquired 25,000 of its ordinary shares at an average price of 208 pence per ordinary share. The ordinary shares purchased yesterday will be held in treasury in order to satisfy the exercise of options granted by the Company under the Cryo-Save Group 2007 Option Scheme.

read more

Transaction in own shares

December 20, 2007 Group News
Tags

Cryo-Save Group N.V. (the “Company”) yesterday acquired 80,000 of its ordinary shares at an average price of 206 pence per ordinary share. The ordinary shares purchased yesterday will be held in treasury in order to satisfy the exercise of options granted by the Company under the Cryo-Save Group 2007 Option Scheme.

read more

Director/PDMR shareholding

December 10, 2007 Group News

Cryo-Save Group N.V. (“Cryo-Save” or “the Company”), Europe’s largest adult stem cell storage bank, announces that on 7 December 2007 the Company granted options to subscribe for ordinary shares in the Company under the Cryo-Save Group 2007 Share Option Scheme. The Company granted 225,000 options to Directors of the Company (as detailed below) and 115,000 options to certain other employees of the Company all at an exercise price of 221p per share, being the price equal to the arithmetic average of the closing mid-market price over the five dealing days prior to the date of the grant.

read more

Cryo-save Group N.V. first day of dealings

November 6, 2007 Group News
Tags

Cryo-Save Group N.V. (“Cryo-Save”, “the Group” or “the Company”), Europe’s largest adult stem cell storage bank, announces the commencement of dealings in its Ordinary Shares on AIM today under the ticker code CRYO.L and the ISIN number of NL0006091969.

The Group is a profitable emerging healthcare services group whose business focuses on the collection, processing and storage of human adult stem cells collected from the umbilical cord at birth. It currently trades in 36 countries, principally in Europe and operates four laboratories where it has to date stored in excess of 65,000 stem cell samples.

read more

Cryo-Save Group N.V.: admission to aim with market capitalisation of £101.2M

November 1, 2007 Group News

Cryo-Save Group N.V. (“Cryo-Save”, “the Group” or “the Company”), Europe’s largest adult stem cell storage bank, is to be admitted to AIM with a market capitalisation of £101.17 million. The Group has raised £26.54 million, before expenses, via a placing of shares at 210p per share with institutional investors. Trading in Cryo-Save shares is expected to start on Tuesday 6 November 2007.

read more

Portuguese child successfully treated with private stored stem cells

July 16, 2007 Group News

Porto / Brussels July 16 2007. – A child suffering from a severe T-cell (CD8+) immune deficiency syndrome has been treated successfully with umbilical cord blood stem cells in Portugal. The child’s congenital dificiency was clinically diagnosed in Coimbra. The transplantation treatment was performed at the Bone Marrow Transplantation Unit, lead by director Dr. Pedro Pimentel at the Oncology Institute in Porto. Dr. Alzira Carvalhais is the head of the Immuno-Hemato Therapy Department.

read more

Page 43 of 43« First...102030...3940414243